Novocure’s Chief Science Officer Retires after 17 Years of Service

March 21, 2019 Off By BusinessWire

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon
Kirson, Novocure’s Chief Science Officer and Head of Research and
Development, effective May 1, 2019. Dr. Kirson will step away from the
healthcare industry and frequent international travel to spend more time
with his family.

“While this was a difficult decision, it is the right one for my
family,” stated Dr. Kirson. “I intend to remain available to management
and look forward to supporting the company as a Senior Advisor.
Novocure’s culture is strong, and I know I am leaving behind a
professional and capable team who share my dream to extend survival in
some of the most aggressive forms of cancer.”

“Eilon has been a core member of Novocure’s leadership team since the
earliest days, and we are deeply grateful for his professional
leadership and personal friendship,” said Mr. Bill Doyle, Novocure’s
Executive Chairman, and Mr. Asaf Danziger, Novocure’s Chief Executive
Officer. “We wish Eilon the very best for the future.”

Dr. Kirson has committed to ensure a seamless transition of his
responsibilities. The leadership transition presents an opportunity for
Novocure to separate responsibility for medical and scientific affairs,
ensuring appropriate focus as the clinical platform continues to expand.
Effective immediately, Dr. Uri Weinberg, Novocure’s Vice President of
Clinical Development, will assume responsibilities for preclinical and
clinical development and regulatory affairs. Effective April 1, 2019,
Dr. Ely Benaim will join Novocure as Chief Medical Officer and will
assume responsibilities for clinical operations, medical affairs and
medical safety.

About Novocure

Novocure is a global oncology company working to extend survival in some
of the most aggressive forms of cancer by developing and commercializing
its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is
a cancer therapy that uses electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s commercialized
product is approved for the treatment of adult patients with
glioblastoma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in mesothelioma, brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver
cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
timing of clinical milestones, development of potential products,
interpretation of clinical results, prospects for regulatory submission
and approval, manufacturing development and capabilities, market
prospects for its products, coverage, collections from third-party
payers and other statements regarding matters that are not historical
facts. You may identify some of these forward-looking statements by the
use of words in the statements such as “anticipate,” “estimate,”
“expect,” “project,” “intend,” “plan,” “believe” or other words and
terms of similar meaning. Novocure’s performance and financial results
could differ materially from those reflected in these forward-looking
statements due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K filed
on February 28, 2019, with the U.S. Securities and Exchange Commission.
Given these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not rely on
any such factors or forward-looking statements. Furthermore, Novocure
does not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak only as
of the date hereof. The Private Securities Litigation Reform Act of 1995
permits this discussion.